CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jason Coloma

Chief Executive Officer, Maze Therapeutics

Search every verified Jason Coloma interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jason Coloma, chief executive officer of South San Francisco-based Maze Therapeutics, discussed the company's work developing small molecule drugs for kidney diseases on the podcast The Long Run in August 2026. He described Maze's approach as grounded in human genetics, using large data pools to identify variants that cause or protect against illness. The company went public in early 2025 after navigating a period of difficult biotech financing, including a partnership that unraveled after the federal government sought to block it on antitrust grounds, and later secured a new partner for that program. Coloma said the company is positioned to learn within the next year whether its two lead programs, an APOL1-directed kidney drug and another targeting SLC6A19, will pass phase two clinical trial scrutiny. Coloma commented on the lack of approved therapies for APOL1 kidney disease, noting that patients often progress to dialysis with poor outcomes and that current standard-of-care treatments are not working. He also discussed historical challenges in kidney disease drug development, citing a decade without new approvals due to long, outcome-based studies that deterred even large pharmaceutical companies from investing in the area. He expressed hope that within the next year the company could advance to a pivotal study on its APOL1 program and continue developing other programs through mid-stage trials, potentially through partnerships or internal efforts.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →